BTG Pactual Asset Management US LLC Grows Position in Royalty Pharma PLC $RPRX

BTG Pactual Asset Management US LLC boosted its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 18.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 70,732 shares of the biopharmaceutical company’s stock after buying an additional 11,073 shares during the quarter. BTG Pactual Asset Management US LLC’s holdings in Royalty Pharma were worth $3,966,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Headlands Technologies LLC purchased a new position in shares of Royalty Pharma during the second quarter valued at approximately $5,087,000. Greenleaf Trust bought a new stake in Royalty Pharma in the 2nd quarter worth approximately $233,000. Public Employees Retirement System of Ohio purchased a new stake in Royalty Pharma during the 2nd quarter valued at $7,838,000. Monetta Financial Services Inc. purchased a new stake in Royalty Pharma during the 2nd quarter valued at $1,682,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Royalty Pharma during the 2nd quarter valued at $882,000. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX stock opened at $60.85 on Monday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.80 and a quick ratio of 2.80. The company has a market cap of $34.99 billion, a price-to-earnings ratio of 41.97, a PEG ratio of 1.42 and a beta of 0.43. Royalty Pharma PLC has a 1 year low of $34.08 and a 1 year high of $62.46. The firm has a fifty day moving average price of $58.16 and a 200-day moving average price of $52.50.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The company had revenue of $674.14 million for the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%. As a group, equities analysts predict that Royalty Pharma PLC will post 5.3 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 annualized dividend and a dividend yield of 1.5%. Royalty Pharma’s dividend payout ratio (DPR) is 64.83%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of research reports. Wall Street Zen downgraded Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a report on Wednesday, August 5th. TD Cowen raised their target price on Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Morgan Stanley restated an “overweight” rating and set a $65.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Eight investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $60.86.

Insider Activity

In related news, EVP Christopher Hite sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $54.40, for a total transaction of $8,160,000.00. Following the completion of the transaction, the executive vice president directly owned 559,399 shares in the company, valued at approximately $30,431,305.60. The trade was a 21.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 9,099 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $55.88, for a total transaction of $508,452.12. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 398,197 shares of company stock worth $22,513,280 in the last ninety days. Corporate insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.